Cameco Secures Major Indian Uranium Contract Amid Sector Volatility

Cameco signs major long-term uranium supply deal with India, but its stock falls as broader risk-off sentiment hits the uranium sector, highlighting a disconnect between fundamentals and market mood.

Despite announcing a substantial long-term supply agreement with India valued at approximately C$2.6 billion, shares of the Canadian uranium producer Cameco faced notable selling pressure in subsequent trading sessions. The market reaction appeared less tied to company-specific concerns and more indicative of a broader risk-off sentiment sweeping the uranium sector, raising questions about the deal's immediate impact.

A Strategic Partnership for Nuclear Fuel Supply

The contract was finalized during the first official visit to India by Canadian Prime Minister Mark Carney. Cameco entered into the agreement with India’s Department of Atomic Energy, committing to supply nearly 22 million pounds of uranium concentrate (U3O8) between 2027 and 2035. Pricing will be linked to prevailing market conditions.

Based on a uranium price of $86.95 per pound, Cameco estimated the value of the deal. This marks a continuation of the partnership, following a previous five-year supply contract with India that commenced in 2015.

This commercial agreement forms part of a wider diplomatic and economic rapprochement between the two nations. Officials described it as a "landmark deal" for long-term uranium supply, alongside initiatives for a new defense dialogue and a goal to boost bilateral trade to $50 billion by 2030.

India's ambitious energy plans underpin the demand. The country currently operates 24 nuclear reactors with a capacity of 7,943 MW, with six more under construction that will add 4,768 MW. India is targeting 100 GW of nuclear capacity by 2047. Furthermore, legislative changes enacted in December 2025 are designed to attract private investment and relax liability rules that had previously hindered new construction. According to TD Cowen analyst Craig Hutchison, the contract volume represents roughly 12% of Cameco's annual uranium concentrate production.

Share Price Decline Reflects Broader Sector Correction

Notwithstanding the positive news headline, Cameco's stock encountered significant pressure. By Friday, March 6, 2026, shares were down 3.9% intraday, touching a low of $108.66 before settling at $109.77. This contributed to a weekly decline of 7.36%, closing at $109.68.

Market commentary suggests this pullback is part of a wider correction across uranium equities, triggered by a cooling momentum in the underlying commodity price. After reaching highs in January, the spot price for uranium moderated in February. Futures were recently quoted in the mid-$80s per pound, down from late-January peaks.

Activity in the options market also signaled increased caution. On that Friday, trading volume surged, with 28,210 put options purchased. This figure was 942% above the typical volume of 2,706, indicating a notable rise in defensive positioning by traders.

Financial Performance and Strategic Investments

Cameco's most recent quarterly report, released on February 13, showed earnings per share of $0.36, surpassing the consensus estimate of $0.29. Revenue reached $874.57 million, also exceeding expectations of $782.13 million and representing a 1.5% increase over the same quarter the prior year.

The company's valuation remains elevated, with a price-to-earnings (P/E) ratio cited at 117.73. This premium reflects significant anticipated future growth, which could become more vulnerable if uranium prices move sideways or geopolitical factors disrupt supply chains.

The article also highlighted Cameco's 49% stake in Global Laser Enrichment (GLE). In January 2026, GLE secured funding commitment from the U.S. Department of Energy. A successful external validation completed in October 2025 was noted to have substantially de-risked Cameco's investment, with a commercial production start targeted for 2030.